Kazuma Kobayashi1,2,3, Naoya Murakami4, Kana Takahashi4, Koji Inaba4, Ryuji Hamamoto5,2,3, Jun Itami4. 1. Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo, Japan kazumkob@ncc.go.jp. 2. Cancer Translational Research Team, RIKEN Center for Advanced Intelligence Project, Tokyo, Japan. 3. Department of NCC Cancer Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. 4. Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan. 5. Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo, Japan.
Abstract
BACKGROUND/AIM: The aim of this study was to compare the clinical outcomes of patients treated by local radiotherapy or chemotherapy for oligo-recurrent cervical cancer with prior pelvic irradiation. PATIENTS AND METHODS: Forty-one patients who had received pelvic irradiation for cervical cancer developed oligo-recurrent (≤5 lesions) relapses and underwent local radiotherapy (n=22) or systemic chemotherapy (n=19). Overall survival (OS), local recurrence-free survival (LRFS) and distant-free survival (DFS) were estimated, and risk factors were identified. RESULTS: The median follow-up was 24.1 months. The group of local radiotherapy showed a significantly superior LRFS, but inferior DFS. There was no significant difference in OS. Multivariate analysis revealed that FIGO stage at initial diagnosis was associated with OS. For patients with early FIGO stages (IB-IIB), local radiotherapy provided a tendency toward longer OS than chemotherapy. CONCLUSION: Out-field oligo-recurrence in patients with initial early FIGO stages may be an indication of salvage radiotherapy. Copyright
BACKGROUND/AIM: The aim of this study was to compare the clinical outcomes of patients treated by local radiotherapy or chemotherapy for oligo-recurrent cervical cancer with prior pelvic irradiation. PATIENTS AND METHODS: Forty-one patients who had received pelvic irradiation for cervical cancer developed oligo-recurrent (≤5 lesions) relapses and underwent local radiotherapy (n=22) or systemic chemotherapy (n=19). Overall survival (OS), local recurrence-free survival (LRFS) and distant-free survival (DFS) were estimated, and risk factors were identified. RESULTS: The median follow-up was 24.1 months. The group of local radiotherapy showed a significantly superior LRFS, but inferior DFS. There was no significant difference in OS. Multivariate analysis revealed that FIGO stage at initial diagnosis was associated with OS. For patients with early FIGO stages (IB-IIB), local radiotherapy provided a tendency toward longer OS than chemotherapy. CONCLUSION: Out-field oligo-recurrence in patients with initial early FIGO stages may be an indication of salvage radiotherapy. Copyright
Authors: Matthew S Ning; Vamsi Ahobila; Anuja Jhingran; Shane R Stecklein; Michael Frumovitz; Kathleen M Schmeler; Patricia J Eifel; Ann H Klopp Journal: Gynecol Oncol Date: 2017-10-28 Impact factor: 5.482
Authors: G Ferrandina; P A Margariti; D Smaniotto; M Petrillo; M G Salerno; A Fagotti; G Macchia; A G Morganti; N Cellini; G Scambia Journal: Gynecol Oncol Date: 2010-12 Impact factor: 5.482
Authors: Simon S Lo; Susan D Moffatt-Bruce; Laura A Dawson; Roderich E Schwarz; Bin S Teh; Nina A Mayr; Jiade J Lu; John C Grecula; Thomas E Olencki; Robert D Timmerman Journal: Nat Rev Clin Oncol Date: 2011-05-24 Impact factor: 66.675
Authors: Aniek Boers; Henriette J G Arts; Harry Klip; Esther R Nijhuis; Elisabeth Pras; Harry Hollema; G Bea A Wisman; Hans W Nijman; Marian J E Mourits; Anna K L Reyners; Geertruida H de Bock; Gillian Thomas; Ate G J van der Zee Journal: Int J Gynecol Cancer Date: 2014-09 Impact factor: 3.437